Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01547936 · ClinicalTrials.gov registry record
Effect of Controlled Adverse Environment (CAE) on Tear Film Stability
A clinical trial, sponsored by ORA.
- Completed
- Registry status
- 33
- Enrollment target
NCT01547936: Completed study, sponsored by ORA.
NCT01547936 is a clinical trial that has completed, run by ORA. The registered enrollment target is 33 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01547936 has completed, sponsored by ORA.
- COMPLETED
- Registry status
- 33 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effect of the controlled adverse environment (CAE) on Mean Break-Up Area in subjects diagnosed with Dry Eye Syndrome.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2012-02 |
| Est. Completion | 2012-02 |
What the finished NCT01547936 record still lists
NCT01547936 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 33 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT01547936 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01547936 about?
NCT01547936 is a clinical study titled "Effect of Controlled Adverse Environment (CAE) on Tear Film Stability". The purpose of this study is to evaluate the effect of the controlled adverse environment (CAE) on Mean Break-Up Area in subjects diagnosed with Dry Eye Syndrome.
What is the current status of trial NCT01547936?
This trial is currently completed. The enrollment target is 33 participants. The study started on 2012-02. Estimated completion is 2012-02.
Who is sponsoring clinical trial NCT01547936?
This trial is sponsored by ORA, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia